PO.IM02.03 · 免疫学

villin阳性胃祖细胞中PPARdelta过表达在小鼠中驱动胃肿瘤发生且独立于幽门螺杆菌感染

PPARdelta overexpression in villin-positive gastric progenitor cells drive gastric tumorigenesis independent of helicobacter infection in mice

编号 2874 展板 14 时间 4/20 02:00–05:00 区域 Section 9 主讲 Xiangsheng Zuo, MD;PhD
分会场 Microbiome, Inflammation, and Response to Immunotherapy in Cancer
该海报暂无可下载的资料 AACR 官方页面

作者与单位 Authors & Affiliations

Daoyan Wei1, Yi Liu1, James C. Yao1, Imad Shureiqi2, Xiangsheng Zuo1

1UT MD Anderson Cancer Center, Houston, TX,2University of Michigan, Ann Arbor, MI

摘要 Abstract

中文摘要
背景 单一基因PPARdelta在villin阳性胃祖细胞(VGPCs)中过表达已被证明可在villin-PPARdelta小鼠中诱导胃腺癌(GAC)。然而,PPARdelta在小鼠结肠上皮细胞或胰腺祖细胞中单独过表达无法启动肿瘤发生,但可显著加速结肠和胰腺中的肿瘤发展。这些发现提出了是否有其他因素与PPARdelta协同驱动GAC的问题。H. pylori感染是人类GAC的强危险因素。在饲养villin-PPARdelta小鼠的改良SPF屏障中,螺杆菌属未被排除,且被推定为地方性流行。此类螺杆菌感染是否促成PPARdelta驱动的GAC仍属未知。 方法 利用villin-PPARdelta小鼠的冷冻精子通过体外受精生成了一个新的villin-PPARdelta小鼠品系,并饲养于无螺杆菌屏障中。在4周龄时,一半小鼠继续留在无螺杆菌屏障中(villin-PPARdelta-L1),另一半被转移至改良SPF屏障中,在该屏障中饲养小鼠的胃肠道常可检测到螺杆菌属(villin-PPARdelta-L2)。这些小鼠与此前已在改良SPF屏障中饲养多年的villin-PPARdelta小鼠品系(villin-PPARdelta-L3)一起,被随访25、35和55周(每组n=10-12只小鼠)。每个品系的野生型(WT)同窝仔作为对照。所有小鼠均评估肿瘤多发性并接受组织学检查。通过使用qPCR/PCR从小鼠胃内容物和粪便中提取的基因组DNA检测16S rRNA基因,评估螺杆菌属。 结果 在villin-PPARdelta-L1小鼠所有年龄段及villin-PPARdelta-L2小鼠10和25周时均未检测到螺杆菌属,但在villin-PPARdelta-L2小鼠35和55周时以及villin-PPARdelta-L3小鼠所有年龄段中检测到。纵向随访显示胃肿瘤发生以年龄依赖方式进展。大体病变最初在25周时见于胃体小弯侧,并最终在55周时扩展至占据整个胃体。所有在≥25周检查的小鼠至少发展出胃增生。在35周时,约60%的小鼠发展出低级别或高级别胃异型增生,到55周时,约70%发展出GAC,其中包括30%伴有较大的局部侵袭性GAC。慢性炎症存在于胃部病变中,并与肿瘤进展呈正相关。三个villin-PPARdelta小鼠品系之间在胃部炎症和肿瘤发生方面未观察到显著差异。WT对照均未发展出胃肿瘤。 结论 VGPCs中PPARdelta过表达在小鼠中驱动胃肿瘤发生且独立于螺杆菌感染,提示PPARdelta可能是GAC的一个潜在治疗靶点。
查看英文原文 English abstract
Background Overexpression of the single gene PPARdelta in villin-positive gastric progenitor cells (VGPCs) has been shown to induce gastric adenocarcinoma (GAC) in villin-PPARdelta mice. However, PPARdelta overexpression alone in colonic epithelial cells or pancreatic progenitor cells in mice fails to initiate tumorigenesis but dramatically accelerated tumor development in the colon and pancreas. These findings raise the question of whether additional factors cooperate with PPARdelta to drive GAC. H. pylori infection is a strong risk factor for human GAC. In modified SPF barrier where villin-PPARdelta mice are housed, helicobacter species is not excluded and presumed to be endemic. Whether such helicobacter infection contributes to PPARdelta-driven GAC remains unknown. Methods A new villin-PPARdelta mouse line was generated via in vitro fertilization using frozen sperm of villin-PPARdelta mice and housed in helicobacter-free barrier. At 4 weeks of age, half of the mice remained in helicobacter-free barrier (villin-PPARdelta-L1), while the other half were transferred to modified SPF barrier, where helicobacter species is commonly detected in the gastrointestinal tract of housed mice (villin-PPARdelta-L2). These mice, along with the previous villin-PPARdelta mouse line that had been maintained in modified SPF barrier for years (villin-PPARdelta-L3), were followed for 25, 35, and 55 weeks (n =10-12 mice per group). Wild type (WT) littermates from each line were served as controls. All mice were evaluated for tumor multiplicity and subjected to histologic examination. Helicobacter species was assessed by detecting 16S rRNA genes from genomic DNA extracted in mouse stomach contents and stools using qPCR/PCR. Results Helicobacter species was not detectable in villin-PPARdelta-L1 mice at all ages and villin-PPARdelta-L2 mice at 10 and 25 weeks but were detected in villin-PPARdelta-L2 mice at 35 and 55 weeks and villin-PPARdelta-L3 mice at all ages. Longitudinal follow-up revealed that gastric tumorigenesis progressed in an age-dependent manner. Gross lesions were initially found in the lesser curvature of the gastric corpus at 25 weeks and eventually expanded to occupy the whole gastric corpus at 55 weeks. All mice examined at ≥ 25 weeks developed at least gastric hyperplasia. At 35 weeks, approximately 60% of mice developed low-grade or high-grade gastric dysplasia, and by 55 weeks, around 70% developed GACs, including 30% with large, locally invasive GACs. Chronic inflammation was present in gastric lesions and positively correlated with tumor progression. No significant differences in gastric inflammation and tumorigenesis were observed among three villin-PPARdelta mouse lines. None of WT controls developed gastric tumors. Conclusions PPARdelta overexpression in VGPCs drive gastric tumorigenesis independent of helicobacter infection in mice, suggesting that PPARdelta may be a potential therapeutic target for GAC.
利益披露 Disclosure
D. Wei, None.. Y. Liu, None.. J. C. Yao, None.. I. Shureiqi, None.. X. Zuo, None.

← 返回 AACR 2026 检索